Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCS-100 plus R-ICE in relapsed or refractory diffuse large B-cell lymphoma
ISRCTN66315383Phase 2Terminated
- Sponsor
- Prospect Therapeutics
- Start
- Dec 2008
01
Overview
Phase 2, open-label, single-arm trial of GCS-100 in diffuse large B-cell lymphoma (DLBCL), sponsored by Prospect Therapeutics. Primary endpoints: Overall response rate and Imaging-based response assessment. Started Dec 2008; status: terminated.
02
Drugs
GCS-100
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ISRCTN66315383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN66315383.